Anzeige
Meldung des Tages: Wall Street. Trump. Antimon - ATMY steht jetzt im Zentrum politischer Macht und kritischer Versorgung

Citius Oncology Aktie News

Aktie
WKN:  A40K7E ISIN:  US17331Y1091 US-Symbol:  CTOR Branche:  Pharmazeutika Land:  USA
1,055 $
-0,005 $
-0,47%
0,8933 € 17:49:07 Uhr
Depot/Watchlist
Marktkapitalisierung *
68,68 Mio. €
Streubesitz
-
KGV
-6,55
Index-Zuordnung
-

Citius Oncology News

06.08.25 - PR Newswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators PR Newswire
17.07.25 - PR Newswire
Citius Oncology Announces Closing of $9.0 Million Public Offering
Citius Oncology Announces Closing of $9.0 Million Public Offering PR Newswire
16.07.25 - PR Newswire
Citius Oncology Announces Pricing of $9.0 Million Public Offering
Citius Oncology Announces Pricing of $9.0 Million Public Offering PR Newswire
15.07.25 - PR Newswire
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora
Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora PR Newswire
08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
08.07.25 - PR Newswire
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
26.06.25 - PR Newswire
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? PR Newswire
17.06.25 - PR Newswire
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
12.06.25 - PR Newswire
After Major Oncology Conference, All Eyes Turn to Industry Innovation
After Major Oncology Conference, All Eyes Turn to Industry Innovation PR Newswire
09.06.25 - PR Newswire
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health PR Newswire
14.05.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update PR Newswire
14.02.25 - PR Newswire
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update PR Newswire
06.02.25 - PR Newswire
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services PR Newswire

Newssuche

Videos

newspaper
12:40 Uhr +27,72%
Technical Trading Silber Crash!
Silber Short Typ: Turbo Open End WKN: VJ4GQU Hebel: 3,77 Laufzeit: OpenEnd Einstieg: Market ... Mehr »